摘要
目的:观察更昔洛韦联合异甘草酸镁治疗婴儿巨细胞病毒(CMV)肝炎的临床疗效。方法:选择在我院住院治疗的巨细胞病毒肝炎患儿68例,随机分为治疗组38例和对照组30例。治疗组给予更昔洛韦联合异甘草酸镁治疗,对照组单用更昔洛韦治疗,两组其他辅助治疗相同,疗程均为6周。详细记录治疗前后患儿症状、体征、肝功能、肾功能、电解质及血尿常规,同时记录治疗过程中的不良反应。结果:两组患儿治疗后肝功能生化指标与治疗前比较差异有统计学意义(P<0.05);两组治疗后各项生化指标下降程度比较差异有统计学意义(P<0.05),治疗组明显优于对照组;治疗组总有效率89.5%,对照组总有效率43.4%,两组比较差异有统计学意义(P<0.05);治疗组出现的不良反应例数明显少于对照组。结论:更昔洛韦联合异甘草酸镁治疗婴儿巨细胞病毒肝炎疗效显著,而且不良反应少,值得临床推广。
Objective： To observe the clinical efficacy of ganciclovir combined with magnesium isoglycyrrhizinate for cytomegalovirus hepatitis in infants. Methods： A total of 68 hospital inpatients with cytomegalovirus hepatitis were randomly divided into a treatment group （38 cases） and a control group （30 cases）. The treated group received ganciclovir and magnesium isogtycyrrhizinate, and the control group received only ganciclovir. The therapeutic course lasted for six weeks. Children＇ s detailed information, including symptoms, signs, testing results of liver/kidney functions, electrolytes, and hematuria routines were recorded before and after the treatment. Results： Children in both groups showed therapeutic effect with statistical significance in symptom improvement and liver biochemical parameters after treatment（ P〈0.05 ）, and there was also a significant difference between the two groups （P〈0.05）. Patients in the treatment group recovered faster with less adverse reactions than those in the control group. Conclusions： Treating cytomegalovirus hepatitis in infant with ganciclovir and magnesium isoglycyrrhizinate is evidently effective, and is favorably recommended for clinical use.
出处
《儿科药学杂志》
CAS
2013年第4期20-22,共3页
Journal of Pediatric Pharmacy
关键词
更昔洛韦
异甘草酸镁
巨细胞病毒
肝炎
婴儿
Ganciclovir
Magnesium isoglycyrrhizinate
Cytomegalovirus
Hepatitis
Infants
